Avivagen Inc. has announced that it has entered into an agreement with the research subsidiary of COFCO Biotechnology Co. Ltd. ('COFCO') pursuant to which COFCO will assist Avivagen with the approval process necessary to enter the Chinese market. With over 12,000 employees, COFCO is a leading supplier of agri-products to the Chinese market, with more than $17.5 billion in annual sales in 2018. Under the agreement, COFCO will work with Avivagen in China, supporting efforts to obtain approval for the sale of OxC-beta™ Livestock for use with broilers in the country. COFCO Biotechnology will assist Avivagen with all aspects of the approval process in China, including designing all protocols required for trials of OxC-beta™ Livestock necessary to secure approval for use in broiler feed. COFCO has confirmed to Avivagen that the current position of the Chinese government is to ban all antibiotics in livestock feed by July 2020.